Tvardi Therapeutics, Inc. (TVRD)
NASDAQ · Manufacturing · Pharmaceutical preparations
TVRD price, last 12 months
Key stats
- Previous close
- $1.04
- Open
- $1.06
- Day range
- $0.9178 – $1.08
- 52-week range
- $0.7729 – $5.69
- Volume
- 78K
- Avg volume (20 days)
- 363.7K
- Market cap
- $15.7M
Performance
Technicals and fundamentals
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $15.7M